Sage Journals: Discover world-class research

Abstract

There is little European evidence on how originator and generic medicines set prices in the off-patent market and on the factors that influence pricing strategies. The aim of this study was to examine pricing strategies of originator and generic medicines following patent expiry in Belgium. To this effect, the evolution of the public price of originator and generic medicines was investigated from July 2001 to December 2005. Regression and scenario analyses show that the Belgian off-patent market is a segmented market when it comes to pricing. Pricing strategies are influenced by regulatory aspects, such as successive reductions in reference prices and prescription status of medicines; by market incentives in the form of price competition between generic medicines and competition between originator and generic medicines; by medication class; and by market power of the manufacturer of the originator medicine. Therefore, there is no single pricing strategy that authorities or manufacturers can use to predict the pricing behaviour of originator and generic medicines following patent expiry and to foresee the development of the generic medicines market.

Keywords

pricing reference pricing regulation market incentives off-patent market Belgium

Get full access to this article

View all access options for this article.

References

Grabowski

Vernon

(1992). Brand loyalty; entry, and price competition in pharmaceuticals after the 1984 drug act. J Law Econ 35, 331–350.

Frank

R. G.

Salkever

D. S.

(1997). Generic entry and the pricing of pharmaceuticals. J Econ Manage Strategy 6, 75–90.

Caves

R. E.

Whinston

M. D.

Hurwitz

M. A.

(1991). Patent expiry and competition in the US pharmaceutical industry. Brookings Papers on Economic Activity. Microeconomics 1991, 1–48.

Dalen

D. M.

Strom

Haabeth

(2006). Price regulation and generic competition in the pharmaceutical market. Eur J Health Econ 7, 208–214.

Magazzini

Pammolli

Riccaboni

(2004). Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Eur J Health Econ 5, 175–182.

Danzon

P. M.

Chao

L. W.

(2000). Cross-national price differences for pharmaceuticals: How large, and why. J Health Econ 19, 159–195.

Simoens

De Coster

(2006). Sustaining generic medicines markets in Europe. J Generic Med 3, 257–268.

Schulz

(2004). Evolving dynamics of US and European generics markets. J Generic Med 2, 23–32.

de Joncheere

Rietveld

A. H.

Huttin

(2002). Experiences with generics. Int J Risk Safety Med 15, 101–109.

10.

King

D. R.

Kanavos

(2002). Encouraging the use of generic medicines: Implications for transition economies. Croat Med J 43, 462–469.

11.

Simoens

(2007). International comparison of generic medicine prices. Curr Med Res Opin 23, 2647–2654.

12.

Belgian Association of Generic Medicine Manufacturers (2007): http://www.febelgen.be, Belgian Association of Generic Medicine Manufacturers, accessed 21st November, 2007.

13.

Simoens

Verhaegen

Laekeman

Peetermans

W. E.

(2005). Treating respiratory tract infections in ambulatory care in Belgium: Fluoroquinolone consumption and resistance development. Int J Antimicrob Agents 26, 62–68.

14.

General Association of the Medicines Industry (2007): http://www.pharma.be, General Association of the Medicines Industry, accessed 20th November, 2007.

Pricing Strategies of Originator and Generic Medicines following Patent Expiry in Belgium

Abstract

Keywords

Get full access to this article

References